Regenerative Medicine · Cyprus

Bone-Marrow Aspirate Concentrate (BMAC)

Single-puncture harvest of bone-marrow aspirate concentrate (BMAC) from the iliac crest using the closed-tip Marrow Cellution™ cannula. Used as a second-line regenerative option for mild-to-moderate osteoarthritis, focal cartilage defects, bone non-unions, and tendon-repair augmentation. Private-pay regenerative procedure in Cyprus.

Quick Answers

Is BMAC harvest covered by GESY in Cyprus?

No. BMAC is a private-pay regenerative procedure in Cyprus. GESY covers standard orthopaedic procedures and conventional injectables, with autologous biologics in the private tier.

Why is no centrifuge required?

The Marrow Cellution™ closed-tip cannula concentrates marrow inside the cannula, drawing through graduated side-ports in a single iliac-crest puncture. Blood dilution is minimised at the source, so no separate centrifugation step is needed.

Is the iliac-crest harvest painful?

Most patients report mild local soreness at the donor site for 24 to 48 hours, controlled by simple oral analgesia. Local anaesthesia is infiltrated at the aspiration site before the procedure.

What does the published evidence show?

The 2025 ESSKA-ORBIT European consensus (Level I evidence) supports cell-based therapy as a valid second-line injectable option for Kellgren-Lawrence 1 to 3 knee osteoarthritis, with longer-lasting benefit than corticosteroid or hyaluronic acid.

What is Bone-Marrow Aspirate Concentrate (BMAC)?

Also known as: BMAC harvest, Marrow Cellution™ closed-tip aspiration, bone marrow concentrate, single-puncture BMAC, iliac-crest aspiration, autologous mesenchymal cell injection, closed-tip BMA, regenerative bone marrow injection, bone marrow stromal cell harvest, bone marrow stem cell injection, stem cell injection (BMAC)

BMAC (Bone-Marrow Aspirate Concentrate) is the harvest of autologous bone-marrow containing mesenchymal stromal cells and other progenitor cells for regenerative applications. In Cyprus we use the Marrow Cellution™ system from Aspire Medical Innovation, a closed-tip cannula with graduated lateral side-ports that draws marrow from multiple medullary geographies in a single iliac-crest puncture.

The Marrow Cellution™ design produces concentrate directly in the cannula, with no separate centrifugation step. This shortens the procedure, removes a processing step, and avoids the hemolysis and cell loss associated with high-speed centrifugation. OrganoGEN is the exclusive Cyprus distributor.

The 2025 ESSKA-ORBIT European consensus on injectable orthobiologics (de Girolamo et al., Level I evidence) supports cell-based therapy as a second-line injectable option for mild-to-moderate knee osteoarthritis (Kellgren-Lawrence grade 1 to 3), with consistent pain and function improvement up to 12 months and longer-lasting benefit than corticosteroid or hyaluronic acid. In OrganoGEN's regenerative pathway, BMAC sits alongside PRGF (Endoret®), with PRGF as the first-line injectable and BMAC as the second-line option after first-line therapy or for indications where cell-based therapy is specifically preferred.

📋 Procedure at a Glance

Source
Autologous (iliac crest)
Cannula
Marrow Cellution™ closed-tip
Centrifuge
Not required (concentrate produced in-cannula)
Visit time
Under 60 min end-to-end
Anaesthesia
Local at the harvest site (IV sedation or GA where indicated)
GESY
Private-pay (regenerative tier)

Am I a candidate?

Good candidates

  • Mild-to-moderate knee or hip osteoarthritis (Kellgren-Lawrence 1 to 3), as a second-line injectable after first-line PRGF or conventional therapy
  • Focal cartilage defects (knee, ankle, hip)
  • Bone non-unions and delayed unions
  • Tendon-repair augmentation
  • Bone-graft augmentation in combination with a scaffold (e.g. SmartBone® ORTHO)
  • Spine fusion adjunct (surgeon-selected)

Patients in whom another option may be preferred

  • Active local or systemic infection
  • Active malignancy at or near the target site
  • Severely compromised bone marrow or marrow-suppressive treatment
  • End-stage osteoarthritis (Kellgren-Lawrence 4) where joint replacement is the appropriate option
  • Severe coagulopathy or anticoagulation that cannot be safely paused
  • Patient-specific contraindications to autologous blood handling

GESY coverage & out-of-pocket cost

This is a private-pay procedure. BMAC sits in the regenerative tier in Cyprus and is not covered by GESY. GESY covers standard orthopaedic surgical procedures and conventional injectables. Autologous biologics are private-pay. OrganoGEN provides clinic quotations on request. Request a quote.

Devices used in this procedure

Marrow Cellution™ Bone-Marrow Aspirate SystemRegenerative Medicine · BMAC Harvestchevron_right

Where to have Bone-Marrow Aspirate Concentrate (BMAC) in Cyprus

OrganoGEN supplies GESY-contracted hospitals across the island. Contact us for the current list of participating surgeons in:

Talk to a surgeon in Cyprus

OrganoGEN can connect you with a participating GESY-contracted surgeon for a consultation.

Request Referral

Frequently asked questions

Is BMAC harvest covered by GESY in Cyprus?
No. BMAC is a private-pay regenerative procedure in Cyprus. GESY covers standard orthopaedic procedures and conventional injectables. Autologous biologics sit in the private tier.
Why is no centrifuge required?
The Marrow Cellution™ closed-tip cannula concentrates marrow directly in the cannula by drawing through graduated lateral side-ports across multiple medullary geographies in a single iliac-crest puncture. Peripheral-blood dilution is minimised at the source, removing the need for a separate centrifugation step. The concentrate is ready for delivery without leaving the sterile field.
Is the iliac-crest harvest painful?
Most patients report mild local soreness at the donor site for 24 to 48 hours, controlled by simple oral analgesia. Local anaesthesia is infiltrated at the aspiration site before the procedure. IV sedation or general anaesthesia is available where the indication or patient preference requires it.
What does the published evidence show?
The 2025 ESSKA-ORBIT European consensus (de Girolamo et al., Level I evidence) supports cell-based therapy as a valid second-line injectable option for Kellgren-Lawrence 1 to 3 knee osteoarthritis, with consistent pain and function improvement up to 12 months and longer-lasting benefit than corticosteroid or hyaluronic acid. A double-blind randomised controlled trial reported similar outcomes to hyaluronic acid up to 24 months in symptomatic knee osteoarthritis (Boffa 2022, PubMed 34767030). For long-bone non-unions, Hernigou's landmark percutaneous BMAC series established foundational clinical efficacy, with response correlated to the number and concentration of progenitor cells delivered (Hernigou 2005, PubMed 15995108).
How does BMAC fit alongside PRGF in OrganoGEN's regenerative pathway?
PRGF (Endoret®) is the first-line injectable per the 2024 ESSKA-ORBIT consensus (Part 1, Laver et al.). BMAC is positioned as a second-line option per the 2025 ESSKA-ORBIT consensus (Part 2, de Girolamo et al.), to be considered after first-line PRGF or conventional therapy, or where cell-based therapy is specifically preferred (e.g. focal cartilage defects, non-unions, tendon-repair augmentation).
Is the Marrow Cellution™ system regulated?
Yes. The Marrow Cellution™ system is CE marked under the EU Medical Device Regulation (Regulation 2017/745), notified body 2797, and distributed by Aspire Medical Innovation (Munich, Germany).
Where can I have BMAC done in Cyprus?
Through Marrow Cellution-trained clinicians in OrganoGEN's network. Contact us for the current list in Limassol, Nicosia, Larnaca, Paphos, and Famagusta.

Information is educational and not a substitute for individual surgical advice. Patient outcomes vary; please consult a qualified surgeon to discuss whether this procedure is right for you.

arrow_back
BMAC Harvest
Regenerative Medicine · Cyprus

Bone-Marrow Aspirate Concentrate (BMAC)

Also known as: BMAC harvest, Marrow Cellution™ closed-tip aspiration, bone marrow concentrate, single-puncture BMAC, iliac-crest aspiration, autologous mesenchymal cell injection, closed-tip BMA, regenerative bone marrow injection, bone marrow stromal cell harvest, bone marrow stem cell injection, stem cell injection (BMAC)

Single-puncture harvest of bone-marrow aspirate concentrate (BMAC) from the iliac crest using the closed-tip Marrow Cellution™ cannula. Used as a second-line regenerative option for mild-to-moderate osteoarthritis, focal cartilage defects, bone non-unions, and tendon-repair augmentation. Private-pay regenerative procedure in Cyprus.

favoriteAutologousscienceNo centrifugehealingOutpatient

Quick Answers

SourceAutologous (iliac crest)
CannulaMarrow Cellution™ closed-tip
CentrifugeNot required (concentrate produced in-cannula)
Visit timeUnder 60 min end-to-end
AnaesthesiaLocal at the harvest site (IV sedation or GA where indicated)
GESYPrivate-pay (regenerative tier)
Overview

About this procedure

BMAC (Bone-Marrow Aspirate Concentrate) is the harvest of autologous bone-marrow containing mesenchymal stromal cells and other progenitor cells for regenerative applications. In Cyprus we use the Marrow Cellution™ system from Aspire Medical Innovation, a closed-tip cannula with graduated lateral side-ports that draws marrow from multiple medullary geographies in a single iliac-crest puncture.

The Marrow Cellution™ design produces concentrate directly in the cannula, with no separate centrifugation step. This shortens the procedure, removes a processing step, and avoids the hemolysis and cell loss associated with high-speed centrifugation. OrganoGEN is the exclusive Cyprus distributor.

Eligibility

Are you a candidate?

  • check_circleLikely yes: Mild-to-moderate knee or hip osteoarthritis (Kellgren-Lawrence 1 to 3), as a second-line injectable after first-line PRGF or conventional therapy
  • check_circleLikely yes: Focal cartilage defects (knee, ankle, hip)
  • check_circleLikely yes: Bone non-unions and delayed unions
  • check_circleLikely yes: Tendon-repair augmentation
  • check_circleLikely yes: Bone-graft augmentation in combination with a scaffold (e.g. SmartBone® ORTHO)
  • check_circleLikely yes: Spine fusion adjunct (surgeon-selected)
  • cancelNot suitable: Active local or systemic infection
  • cancelNot suitable: Active malignancy at or near the target site
  • cancelNot suitable: Severely compromised bone marrow or marrow-suppressive treatment
  • cancelNot suitable: End-stage osteoarthritis (Kellgren-Lawrence 4) where joint replacement is the appropriate option
  • cancelNot suitable: Severe coagulopathy or anticoagulation that cannot be safely paused
  • cancelNot suitable: Patient-specific contraindications to autologous blood handling
GESY & Cost

GESY coverage & out-of-pocket cost

This is a private-pay procedure. BMAC sits in the regenerative tier in Cyprus and is not covered by GESY. GESY covers standard orthopaedic surgical procedures and conventional injectables. Autologous biologics are private-pay. OrganoGEN provides clinic quotations on request. Request a quote.

Devices used

Devices used in this procedure

Where it's offered in Cyprus

Find a clinic

FAQ

Patient questions

Is BMAC harvest covered by GESY in Cyprus?
No. BMAC is a private-pay regenerative procedure in Cyprus. GESY covers standard orthopaedic procedures and conventional injectables. Autologous biologics sit in the private tier.
Why is no centrifuge required?
The Marrow Cellution™ closed-tip cannula concentrates marrow directly in the cannula by drawing through graduated lateral side-ports across multiple medullary geographies in a single iliac-crest puncture. Peripheral-blood dilution is minimised at the source, removing the need for a separate centrifugation step. The concentrate is ready for delivery without leaving the sterile field.
Is the iliac-crest harvest painful?
Most patients report mild local soreness at the donor site for 24 to 48 hours, controlled by simple oral analgesia. Local anaesthesia is infiltrated at the aspiration site before the procedure. IV sedation or general anaesthesia is available where the indication or patient preference requires it.
What does the published evidence show?
The 2025 ESSKA-ORBIT European consensus (de Girolamo et al., Level I evidence) supports cell-based therapy as a valid second-line injectable option for Kellgren-Lawrence 1 to 3 knee osteoarthritis, with consistent pain and function improvement up to 12 months and longer-lasting benefit than corticosteroid or hyaluronic acid. A double-blind randomised controlled trial reported similar outcomes to hyaluronic acid up to 24 months in symptomatic knee osteoarthritis (Boffa 2022, PubMed 34767030). For long-bone non-unions, Hernigou's landmark percutaneous BMAC series established foundational clinical efficacy, with response correlated to the number and concentration of progenitor cells delivered (Hernigou 2005, PubMed 15995108).
How does BMAC fit alongside PRGF in OrganoGEN's regenerative pathway?
PRGF (Endoret®) is the first-line injectable per the 2024 ESSKA-ORBIT consensus (Part 1, Laver et al.). BMAC is positioned as a second-line option per the 2025 ESSKA-ORBIT consensus (Part 2, de Girolamo et al.), to be considered after first-line PRGF or conventional therapy, or where cell-based therapy is specifically preferred (e.g. focal cartilage defects, non-unions, tendon-repair augmentation).
Is the Marrow Cellution™ system regulated?
Yes. The Marrow Cellution™ system is CE marked under the EU Medical Device Regulation (Regulation 2017/745), notified body 2797, and distributed by Aspire Medical Innovation (Munich, Germany).
Where can I have BMAC done in Cyprus?
Through Marrow Cellution-trained clinicians in OrganoGEN's network. Contact us for the current list in Limassol, Nicosia, Larnaca, Paphos, and Famagusta.